[CEMI] Chembio Diagnostics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 6.75 Change: 0.15 (2.27%)
Ext. hours: Change: 0 (0%)

chart CEMI

Refresh chart

Strongest Trends Summary For CEMI

CEMI is in the medium-term down -27% below S&P in 7 months. In the long-term down -58% below S&P in 2 years and up 41% in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company?s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies and antigens. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with th

Fundamental Ratios
Shares Outstanding EPS-1.39 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -16.06% Sales Growth - Q/Q-12.18% P/E-4.32
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-6.48% ROE-8.13% ROI
Current Ratio3.32 Quick Ratio2.56 Long Term Debt/Equity Debt Ratio0.25
Gross Margin40.01% Operating Margin-7.28% Net Profit Margin-5.56% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-860 K Cash From Operating Activities-940 K Gross Profit2.69 M
Net Profit-650 K Operating Profit-880 K Total Assets24.07 M Total Current Assets16.2 M
Total Current Liabilities4.89 M Total Debt Total Liabilities4.89 M Total Revenue6.23 M
Technical Data
High 52 week7.85 Low 52 week4.04 Last close4.18 Last change-2.34%
RSI26.69 Average true range0.44 Beta0.29 Volume9.76 K
Simple moving average 20 days-15.02% Simple moving average 50 days-25.82% Simple moving average 200 days-31.9%
Performance Data
Performance Week3.47% Performance Month-26.8% Performance Quart-16.06% Performance Half-41.04%
Performance Year-33.23% Performance Year-to-date-26.15% Volatility daily4.04% Volatility weekly9.03%
Volatility monthly18.51% Volatility yearly64.12% Relative Volume90.03% Average Volume57.38 K
New High New Low


2020-06-04 17:45:34 | Hedge Funds Are Buying Chembio Diagnostics Inc CEMI

2020-06-04 10:10:02 | Looking For High Earnings Yield? Check Out These 5 Stocks

2020-06-02 08:00:10 | Chembio Diagnostics Strengthens Commercial Organization

2020-05-26 16:15:10 | Chembio Diagnostics to Participate in Upcoming Investor Conferences

2020-05-18 07:00:10 | Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel

2020-05-11 10:20:50 | Chembio Diagnostics Announces Closing of Public Offering of Common Stock

2020-05-07 08:55:10 | Chembio Diagnostics Announces Pricing of Public Offering of Common Stock

2020-05-06 16:01:10 | Chembio Diagnostics Announces Proposed Public Offering of Common Stock

2020-05-05 16:13:25 | Covid Report: Pfizer Begins Vaccine Study; Test Maker Surges On Demand

2020-05-05 02:35:12 | Edited Transcript of CEMI earnings conference call or presentation 4-May-20 8:30pm GMT

2020-05-04 16:05:10 | Chembio Diagnostics Reports First Quarter 2020 Financial Results

2020-05-04 16:04:10 | Chembio Diagnostics Attains CE Marking for DPP COVID-19 System for IgG and IgM Antibodies

2020-04-27 16:05:10 | Chembio Diagnostics to Report First Quarter 2020 Financial Results on May 4, 2020

2020-04-22 16:40:39 | Some high-demand Covid-19 blood tests are a 'disaster,' says Roche boss

2020-04-22 13:21:00 | The future of successful coronavirus response: Mass testing at work and in church and self-administered tests

2020-04-19 08:13:22 | Chembio’s COVID-19 Test Could Separate It from the Rest of the Pack; Analyst Says ‘Buy’

2020-04-17 10:23:02 | Top Ranked Momentum Stocks to Buy for April 17th

2020-04-16 08:47:12 | Chembio CEMI Jumps: Stock Rises 7.1%

2020-04-16 07:57:26 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Apr. 16, 2020: BBY, PLT, DCAR, TBLT, CEMI

2020-04-15 09:26:23 | Chembio Diagnostics Receives Emergency Use Authorization for DPP COVID-19 System for IgG and IgM Antibodies

2020-04-10 09:54:42 | Chembio Spikes 8% As Covid-19 Antibody Test Picked For Study

2020-04-09 16:05:10 | Chembio Diagnostics and Stony Brook Medicine Collaborate to Identify Coronavirus Survivors

2020-04-08 08:00:10 | Chembio Receives Second UNICEF Order for $1.5 Million

2020-04-02 09:25:01 | Company News for Apr 2, 2020

2020-04-01 07:38:15 | The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

2020-03-31 21:10:59 | Chembio Announces Launch of DPP COVID-19 Serological Point-of-Care Test

2020-03-20 08:30:10 | Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635c4

2020-03-20 08:00:10 | Chembio Diagnostics Receives $4 Million Purchase Order from Bio-Manguinhos for Production of DPP COVID-19 IgM/IgG System in Brazil

2020-03-15 08:47:41 | Chembio Diagnostics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

2020-03-13 19:38:55 | Edited Transcript of CEMI earnings conference call or presentation 12-Mar-20 8:30pm GMT

2020-03-13 07:52:53 | The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

2020-03-12 16:46:14 | Chembio Diagnostics Appoints Richard Eberly As Chief Executive Officer

2020-03-12 16:07:14 | Chembio Diagnostics Reports Fourth Quarter and Full Year 2019 Financial Results

2020-03-12 08:00:10 | Chembio and LumiraDx Announce COVID-19 Strategic Partnership

2020-03-11 16:10:10 | Chembio Diagnostics and Takeda Pharmaceutical Complete Feasibility Study

2020-03-03 17:42:53 | Chembio Diagnostics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

2020-03-03 08:30:10 | Chembio Diagnostics Provides Update on Regulatory Status of DPP HIV-Syphilis System

2020-02-28 09:32:55 | Health Check: How Prudently Does Chembio Diagnostics NASDAQ:CEMI Use Debt?

2020-02-12 07:45:10 | Chembio Diagnostics Receives $1.5 Million UNICEF Order for Multiplex Zika Systems

2020-01-09 16:15:10 | T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer

2020-01-09 16:05:10 | Chembio Diagnostics Announces CEO Transition

2020-01-03 07:55:22 | The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

2020-01-02 16:05:10 | Chembio Diagnostics Provides Update on FDA Submission of DPP HIV-Syphilis Test

2019-12-30 14:05:18 | How Chembio Diagnostics, Inc. NASDAQ:CEMI Can Impact Your Portfolio Volatility

2019-11-27 16:22:11 | Should You Avoid Chembio Diagnostics Inc CEMI Too?

2019-11-25 16:30:10 | Chembio Diagnostics Completes Acquisition of Orangelife

2019-11-15 18:39:07 | Edited Transcript of CEMI earnings conference call or presentation 7-Nov-19 9:30pm GMT

2019-11-14 16:40:00 | Chembio Diagnostics to Participate in Upcoming Investor Conferences

2019-11-12 06:43:17 | Imagine Owning Chembio Diagnostics NASDAQ:CEMI And Wondering If The 35% Share Price Slide Is Justified

2019-11-07 16:05:00 | Chembio Diagnostics Reports Third Quarter 2019 Financial Results